{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:58:53Z","timestamp":1793897933890,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI073755"],"award-info":[{"award-number":["AI073755"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI097241"],"award-info":[{"award-number":["AI097241"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zika virus (ZIKV) is a major public health concern due to the risk of congenital Zika syndrome in developing fetuses and Guillain-Barre syndrome in adults. Currently, there are no approved vaccines available to protect against infection. Adenoviruses are safe and highly immunogenic vaccine vectors capable of inducing lasting humoral and cellular immune responses. Here, we developed two Adenovirus (Ad) vectored Zika virus vaccines by inserting a ZIKV prM-E gene expression cassette into human Ad types 4 (Ad4-prM-E) and 5 (Ad5-prM-E). Immune correlates indicate that Ad5-prM-E vaccination induces both an anti-ZIKV antibody and T-cell responses whereas Ad4-prM-E vaccination only induces a T-cell response. In a highly lethal challenge in an interferon \u03b1\/\u03b2 receptor knockout mice, 80% of Ad5 vaccinated animals and 33% of Ad4 vaccinated animals survived a lethal ZIKV challenge, whereas no animals in the sham vaccinated group survived. In an infection model utilizing immunocompetent C57BL\/6 mice that were immunized and then treated with a blocking anti-IFNAR-1 antibody immediately before ZIKV challenge, 100% of Ad4-prM-E and Ad5-prM-E vaccinated mice survived. This indicates that Ad4-prM-E vaccination is protective without the development of detectable anti-ZIKV antibodies. The protection seen in these highly lethal mouse models demonstrate the efficacy of Ad vectored vaccines for use against ZIKV.<\/jats:p>","DOI":"10.1038\/s41598-018-35755-z","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T17:11:54Z","timestamp":1544807514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-0079","authenticated-orcid":false,"given":"Brianna L.","family":"Bullard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette N.","family":"Corder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-3165","authenticated-orcid":false,"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,20]]},"reference":[{"key":"35755_CR1","unstructured":"Fields, B. N., Knipe, D. M. & Howley, P. M. Fields virology. (Wolters Kluwer Health\/Lippincott Williams & Wilkins 2013)."},{"key":"35755_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0614-8","author":"V Koppolu","year":"2018","unstructured":"Koppolu, V. & Shantha Raju, T. Zika virus outbreak: a review of neurological complications, diagnosis, and treatment options. Journal of NeuroVirology. https:\/\/doi.org\/10.1007\/s13365-018-0614-8 (2018).","journal-title":"Journal of NeuroVirology"},{"key":"35755_CR3","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","volume":"375","author":"B Parra","year":"2016","unstructured":"Parra, B. et al. Guillain\u2013Barr\u00e9 Syndrome Associated with Zika Virus Infection in Colombia. New England Journal of Medicine 375, 1513\u20131523, https:\/\/doi.org\/10.1056\/NEJMoa1605564 (2016).","journal-title":"New England Journal of Medicine"},{"key":"35755_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.aaf6116","volume":"352","author":"PP Garcez","year":"2016","unstructured":"Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 352, 816 (2016).","journal-title":"Science"},{"key":"35755_CR5","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1242\/dev.143768","volume":"143","author":"Q Shao","year":"2016","unstructured":"Shao, Q. et al. Zika virus infection disrupts neurovascular development and results in postnatal microcephaly with brain damage. Development 143, 4127\u20134136, https:\/\/doi.org\/10.1242\/dev.143768 (2016).","journal-title":"Development"},{"key":"35755_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02499-9","volume":"9","author":"AJ Hirsch","year":"2018","unstructured":"Hirsch, A. J. et al. Zika virus infection in pregnant rhesus macaques causes placental dysfunction and immunopathology. Nature communications 9, 263 (2018).","journal-title":"Nature communications"},{"key":"35755_CR7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1602113","volume":"374","author":"LR Petersen","year":"2016","unstructured":"Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika Virus. New England Journal of Medicine 374, 1552\u20131563, https:\/\/doi.org\/10.1056\/NEJMra1602113 (2016).","journal-title":"New England Journal of Medicine"},{"key":"35755_CR8","unstructured":"Organization, W. H. 2018 Annual review of diseases prioritized under the Research and Development Blueprint. WHO Research and Development Blueprint (2018)."},{"key":"35755_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nm.4322","volume":"23","author":"C Shan","year":"2017","unstructured":"Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nature Medicine 23, 763\u2013767 (2017).","journal-title":"Nature Medicine"},{"key":"35755_CR10","doi-asserted-by":"publisher","unstructured":"Shan, C. et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications 8, https:\/\/doi.org\/10.1038\/s41467-017-00737-8 (2017).","DOI":"10.1038\/s41467-017-00737-8"},{"key":"35755_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","volume":"170","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell 170, 273\u2013283. e212 (2017).","journal-title":"Cell"},{"key":"35755_CR12","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132, https:\/\/doi.org\/10.1126\/science.aah6157 (2016).","journal-title":"Science"},{"key":"35755_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep46375","volume":"7","author":"K Sumathy","year":"2017","unstructured":"Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Scientific Reports 7, 46375, https:\/\/doi.org\/10.1038\/srep46375 (2017).","journal-title":"Scientific Reports"},{"key":"35755_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"35755_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10595-5","volume":"7","author":"JF Han","year":"2017","unstructured":"Han, J. F. et al. Immunization with truncated envelope protein of Zika virus induces protective immune response in mice. Sci Rep 7, 10047, https:\/\/doi.org\/10.1038\/s41598-017-10595-5 (2017).","journal-title":"Sci Rep"},{"key":"35755_CR16","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1016\/j.vaccine.2017.04.052","volume":"35","author":"M Yang","year":"2017","unstructured":"Yang, M., Dent, M., Lai, H., Sun, H. & Chen, Q. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine 35, 4287\u20134294, https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.052 (2017).","journal-title":"Vaccine"},{"key":"35755_CR17","doi-asserted-by":"publisher","unstructured":"Yang, M., Sun, H., Lai, H., Hurtado, J. & Chen, Q. Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice. Plant Biotechnol J, https:\/\/doi.org\/10.1111\/pbi.12796 (2017).","DOI":"10.1111\/pbi.12796"},{"key":"35755_CR18","doi-asserted-by":"publisher","unstructured":"Yi, G. et al. A DNA Vaccine Protects Human Immune Cells against Zika Virus Infection in Humanized Mice. EBioMedicine, https:\/\/doi.org\/10.1016\/j.ebiom.2017.10.006.","DOI":"10.1016\/j.ebiom.2017.10.006"},{"key":"35755_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.21","volume":"1","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. npj Vaccines 1, 16021 (2016).","journal-title":"npj Vaccines"},{"key":"35755_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid Development of a DNA Vaccine for Zika Virus. Science (New York, N.Y.) 354, 237\u2013240, https:\/\/doi.org\/10.1126\/science.aai9137 (2016).","journal-title":"Science (New York, N.Y.)"},{"key":"35755_CR21","doi-asserted-by":"publisher","unstructured":"Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. The Lancet, https:\/\/doi.org\/10.1016\/S0140-6736(17)33105-7.","DOI":"10.1016\/S0140-6736(17)33105-7"},{"key":"35755_CR22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 168, 1114\u20131125.e1110, https:\/\/doi.org\/10.1016\/j.cell.2017.02.017 (2017).","journal-title":"Cell"},{"key":"35755_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00193-w","volume":"7","author":"JS Chahal","year":"2017","unstructured":"Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8\u2009+\u2009T cell responses in a mouse model. Sci Rep 7, 252, https:\/\/doi.org\/10.1038\/s41598-017-00193-w (2017).","journal-title":"Sci Rep"},{"key":"35755_CR24","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature advance online publication, (2017)."},{"key":"35755_CR25","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.4049\/jimmunol.1602180","volume":"198","author":"D Betancourt","year":"2017","unstructured":"Betancourt, D., de Queiroz, N. M. G. P., Xia, T., Ahn, J. & Barber, G. N. Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity. The Journal of Immunology 198, 3023\u20133028, https:\/\/doi.org\/10.4049\/jimmunol.1602180 (2017).","journal-title":"The Journal of Immunology"},{"key":"35755_CR26","doi-asserted-by":"publisher","first-page":"eaao4163","DOI":"10.1126\/scitranslmed.aao4163","volume":"9","author":"P Abbink","year":"2017","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Science translational medicine 9, eaao4163 (2017).","journal-title":"Science translational medicine"},{"key":"35755_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","volume":"13","author":"E Kim","year":"2016","unstructured":"Kim, E. et al. Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine 13, 315\u2013320, https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.028 (2016).","journal-title":"EBioMedicine"},{"key":"35755_CR28","doi-asserted-by":"crossref","unstructured":"Xu, K. et.al. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M\/E Protects against Zika Virus Infection and Testis Damage (2018).","DOI":"10.1128\/JVI.01722-17"},{"key":"35755_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15039-8","volume":"7","author":"AC Brault","year":"2017","unstructured":"Brault, A. C. et al. A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model. Scientific Reports 7, 14769, https:\/\/doi.org\/10.1038\/s41598-017-15039-8 (2017).","journal-title":"Scientific Reports"},{"key":"35755_CR30","doi-asserted-by":"publisher","first-page":"e0006210","DOI":"10.1371\/journal.pntd.0006210","volume":"12","author":"MA Salvo","year":"2018","unstructured":"Salvo, M. A., Kingstad-Bakke, B., Salas-Quinchucua, C., Camacho, E. & Osorio, J. E. Zika virus like particles elicit protective antibodies in mice. PLOS Neglected Tropical Diseases 12, e0006210, https:\/\/doi.org\/10.1371\/journal.pntd.0006210 (2018).","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"35755_CR31","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","volume":"12","author":"C Zhang","year":"2016","unstructured":"Zhang, C. & Zhou, D. Adenoviral vector-based strategies against infectious disease and cancer. Human Vaccines & Immunotherapeutics 12, 2064\u20132074, https:\/\/doi.org\/10.1080\/21645515.2016.1165908 (2016).","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"35755_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WSM Wold","year":"2013","unstructured":"Wold, W. S. M. & Toth, K. Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. Current gene therapy 13, 421\u2013433 (2013).","journal-title":"Current gene therapy"},{"key":"35755_CR33","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","volume":"28","author":"TC Mast","year":"2010","unstructured":"Mast, T. C. et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28, 950\u2013957, https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.145 (2010).","journal-title":"Vaccine"},{"key":"35755_CR34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1086\/314498","volume":"178","author":"SL Ludwig","year":"1998","unstructured":"Ludwig, S. L. et al. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. The Journal of Infectious Diseases 178, 1776\u20131778 (1998).","journal-title":"The Journal of Infectious Diseases"},{"key":"35755_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4161\/hv.27238","volume":"10","author":"EA Weaver","year":"2014","unstructured":"Weaver, E. A. Vaccines within vaccines: The use of adenovirus types 4 and 7 as influenza vaccine vectors. Human Vaccines & Immunotherapeutics 10, 544\u2013556, https:\/\/doi.org\/10.4161\/hv.27238 (2014).","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"35755_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14891-y","volume":"7","author":"A Lingel","year":"2017","unstructured":"Lingel, A., Bullard, B. L. & Weaver, E. A. Efficacy of an Adenoviral Vectored Multivalent Centralized InfluenzaVaccine. Scientific Reports 7, 14912, https:\/\/doi.org\/10.1038\/s41598-017-14891-y (2017).","journal-title":"Scientific Reports"},{"key":"35755_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","volume":"21","author":"A Elong Ngono","year":"2017","unstructured":"Elong Ngono, A. et al. Mapping and Role of the CD8\u2009+\u2009T Cell Response During Primary Zika Virus Infection in Mice. Cell Host Microbe 21, 35\u201346, https:\/\/doi.org\/10.1016\/j.chom.2016.12.010 (2017).","journal-title":"Cell Host Microbe"},{"key":"35755_CR38","doi-asserted-by":"publisher","unstructured":"Huang, H. et al. CD8\u2009+\u2009T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection. J Virol 91, https:\/\/doi.org\/10.1128\/JVI.00900-17 (2017).","DOI":"10.1128\/JVI.00900-17"},{"key":"35755_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","volume":"19","author":"HM Lazear","year":"2016","unstructured":"Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host & Microbe 19, 720\u2013730, https:\/\/doi.org\/10.1016\/j.chom.2016.03.010 (2016).","journal-title":"Cell Host & Microbe"},{"key":"35755_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.chom.2018.04.003","volume":"23","author":"MJ Gorman","year":"2018","unstructured":"Gorman, M. J. et al. An Immunocompetent Mouse Model of Zika Virus Infection. Cell Host & Microbe 23, 672\u2013685.e676, https:\/\/doi.org\/10.1016\/j.chom.2018.04.003 (2018).","journal-title":"Cell Host & Microbe"},{"key":"35755_CR41","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","volume":"16","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell reports 16, 1485\u20131491, https:\/\/doi.org\/10.1016\/j.celrep.2016.07.049 (2016).","journal-title":"Cell reports"},{"key":"35755_CR42","doi-asserted-by":"publisher","first-page":"e0004682","DOI":"10.1371\/journal.pntd.0004682","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota, M. T. et al. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Neglected Tropical Diseases 10, e0004682, https:\/\/doi.org\/10.1371\/journal.pntd.0004682 (2016).","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"35755_CR43","doi-asserted-by":"publisher","first-page":"e0005296","DOI":"10.1371\/journal.pntd.0005296","volume":"11","author":"DR Smith","year":"2017","unstructured":"Smith, D. R. et al. Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type IInterferon. PLoS Neglected Tropical Diseases 11, e0005296, https:\/\/doi.org\/10.1371\/journal.pntd.0005296 (2017).","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"35755_CR44","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","volume":"17","author":"MO Lasaro","year":"2009","unstructured":"Lasaro, M. O. & Ertl, H. C. New insights on adenovirus as vaccine vectors. Molecular Therapy 17, 1333\u20131339 (2009).","journal-title":"Molecular Therapy"},{"key":"35755_CR45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"N Tatsis","year":"2004","unstructured":"Tatsis, N. & Ertl, H. C. J. Adenoviruses as vaccine vectors. Molecular Therapy 10, 616\u2013629, https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.013 (2004).","journal-title":"Molecular Therapy"},{"key":"35755_CR46","unstructured":"Holst, P. J. & Thomsen, A. R. In Viral Gene Therapy (ed. Ke Xu) Ch. 08 (InTech 2011)."},{"key":"35755_CR47","doi-asserted-by":"publisher","first-page":"e41936","DOI":"10.1371\/journal.pone.0041936","volume":"7","author":"MC Keefer","year":"2012","unstructured":"Keefer, M. C. et al. A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE 7, e41936, https:\/\/doi.org\/10.1371\/journal.pone.0041936 (2012).","journal-title":"PLoS ONE"},{"key":"35755_CR48","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/infdis\/jiu485","volume":"211","author":"LR Baden","year":"2015","unstructured":"Baden, L. R. et al. Induction of HIV-1\u2013Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. The Journal of Infectious Diseases 211, 518\u2013528, https:\/\/doi.org\/10.1093\/infdis\/jiu485 (2015).","journal-title":"The Journal of Infectious Diseases"},{"key":"35755_CR49","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.4049\/jimmunol.1601949","volume":"198","author":"CW Winkler","year":"2017","unstructured":"Winkler, C. W. et al. Adaptive Immune Responses to Zika Virus Are Important for Controlling Virus Infection and Preventing Infection in Brain and Testes. J Immunol 198, 3526\u20133535, https:\/\/doi.org\/10.4049\/jimmunol.1601949 (2017).","journal-title":"J Immunol"},{"key":"35755_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1128\/JVI.76.1.127-135.2002","volume":"76","author":"V Molinier-Frenkel","year":"2002","unstructured":"Molinier-Frenkel, V. et al. Adenovirus Hexon Protein Is a Potent Adjuvant for Activation of a Cellular Immune Response. Journal of Virology 76, 127\u2013135, https:\/\/doi.org\/10.1128\/JVI.76.1.127-135.2002 (2002).","journal-title":"Journal of Virology"},{"key":"35755_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S1473-3099(12)70345-6","volume":"13","author":"M Gurwith","year":"2013","unstructured":"Gurwith, M. et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. The Lancet Infectious Diseases 13, 238\u2013259, https:\/\/doi.org\/10.1016\/S1473-3099(12)70345-6 (2013).","journal-title":"The Lancet Infectious Diseases"},{"key":"35755_CR52","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","volume":"353","author":"K Stettler","year":"2016","unstructured":"Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823\u2013826, https:\/\/doi.org\/10.1126\/science.aaf8505 (2016).","journal-title":"Science"},{"key":"35755_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10901-1","volume":"7","author":"J George","year":"2017","unstructured":"George, J. et al. Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques. Scientific Reports 7, 10498, https:\/\/doi.org\/10.1038\/s41598-017-10901-1 (2017).","journal-title":"Scientific Reports"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35755-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:39:08Z","timestamp":1671626348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35755-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35755-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,20]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.D. is a consultant for Inbios and is on the Scientific Advisory Board of Moderna.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"18017"}}